BTLA has been reported to mark a high-checkpoint-expressing T-cell subset (PD-1, TIM-3, LIGHT, and LAG-3) with decreased cytolytic function and increased proliferation ability, thus correlating with poor prognosis in DLBCL (13, 45). This evidence concerns the gene TNFSF14 and diffuse large B-cell lymphoma.